Dr.T.V.Rao MD
HELICOBACTER PYLORI
UPDATE
DR.T.V.RAO MD 1
HISTORY OF H. PYLORI
• 1890’s: Spirochetes in animal stomachs
• 1900’s: Spirochetes in human stomachs
• 1954: No bacteria in gastric biopsies of 1000 patients
• 1975: Gram negative bacteria in 80% of GU’s
(Pseudomonas)
• 1983: Warren and Marshall characterize H. pylori
• 2005 Nobel prize in 2005
HELICOBACTER PYLORI
Background
Human stomach long considered inhospitable for
bacteria
Spiral shaped organisms occasionally visualized in
gastric mucous layer, but no evidence of disease
association
Organism classified first as Campylobacter pylori
Now Helicobacter pylori
Other species of Helicobacter isolated from
stomach, intestine of other animals
Marshall and Warren culture organism from human
gastric mucosa and show association with gastric
inflammation
DR.T.V.RAO MD 3
HELICOBACTER
( WARREN AND MARSHAL )
• Campylobacter like organisms
• Spiral shaped colonizes Gastric mucosa
• Etiological agent in Gastritis and peptic ulcer
• Most important bacteria.
Helicobacter pylori
Colonizes 50 % of the Individuals
DR.T.V.RAO MD 4
WARREN AND MARSHAL WINS
NOBEL PRIZE
DR.T.V.RAO MD 5
GENERAL CHARACTERISTICS OF
HELICOBACTER
DR.T.V.RAO MD 6
• Helicobacter pylori is major human pathogen associated with
gastric antral epithelium in patients with active chronic gastritis
• Stomach of many animal species also colonized
• Urease (gastric strains only), mucinase, and catalase positive
highly motile microorganisms
• Other Helicobacters: H. cinnaedi and H. fenneliae
• Colonize human intestinal tract
• Isolated from homosexual men with proctitis, proctocolitis,
enteritis, and bacteremia and are often transmitted through
sexual practices
A silver stain of H. pylori on gastric mucus-
secreting epithelial cells (x1000).
From Dr. Marshall's stomach biopsy taken 8 days
after he drank a culture of H. pylori (1985).
DR.T.V.RAO MD 7
HELICOBACTER PYLORI
• Gram –ve spiral
shaped , motile
with unipolar tuft
of lopotrichus
flagella
DR.T.V.RAO MD 8
H. PYLORI BACTERIA
• Gram negative
• Spiral rod
• Unipolar flagella
• Microaerophilic
• Urease positive*
*Most important
character
*Scanning microscopic view of H. pylori
MORPHOLOGY & PHYSIOLOGY OF
HELICOBACTER
DR.T.V.RAO MD 10
• Gram-negative; Helical (spiral or curved) (0.5-1.0 um X
2.5-5.0 um); Blunted/rounded ends in gastric biopsy
specimens; Cells become rod-like and coccoid on
prolonged culture
• Produce urease, mucinase, and catalase
• H. pylori tuft (lophotrichous) of 4-6 sheathed flagella
(30um X 2.5nm) attached at one pole
• Single polar flagellum on H. fennellae & H. cinaedi
• Smooth cell wall with unusual fatty acids
• Transmissible
• Oral-oral and oral-
fecal
• Infects the human
stomach
• Produces inflammatory
response
• This brings up the point
of the importance of
“hand washing”
H. PYLORI INFECTION
TRANSMISSION
DYNAMICS OF H.PYLORI INFECTION
DR.T.V.RAO MD 12
CULTURING AND BIOCHEMICAL
CHARACTERS
• Grows on chocolate agar, Campylobacter media
• Grows under Microaerophilic conditions
• With presence of 5 – 20% co2
• Oxidase +
• Catalase –
• Urease strongly +++
• H2S
DR.T.V.RAO MD 13
H. PYLORI PATHOGENESIS
BACTERIAL VIRULENCE FACTORS
(CAG- PAI)( 37000 B-P – 29 GENES)
• Type IV secretions apparatus(1) (translocate cag A)
• Possible insertion by needle like organelle coated with a sheath (Cag 7
protein) [Rohde et al]
• Phosphorylated + binds to SHP-2 tyrosine Phosphates
Cytokine Production Growth Factor
IL- 8+ chemokines Like cellular response
(1) Odenbreit S, et al. Science 2000;287:1497-1500
H. PYLORI PATHOGENESIS
BACTERIAL VIRULENCE FACTORS
Ingestion Evasion + Entrance of Mucus
1 Layer (Motility + Urea I)
2 Binding
3 Insertion
4 Intra cellular pathway
HELICOBACTER PYLORI AND PEPTIC ULCER DISEASE
HISTOPATHOLOGY WITH SPECIAL STAINS .
DR.T.V.RAO MD 17
H. PYLORI PATHOGENESIS
THE ROLE OF CYTOKINES
I. Alter secretion of mucus
II. TNF–α IL–Iß, INF- 1Y
• ↑ Gastrin release Stimulate parietal cells
↑ Acid secretion
I. TNF–α ↓ D cells number
↓ Somatostatin
↑ Acid secretion
PATHOLOGY AND PATHOGENESIS
• H.pylori colonizes gastric mucosa
• Spread by oral – oral contact
• Feco oral spread prominent
• Poverty and overcrowding predisposes
• Poor Hygiene
• Causes mild to acute gastritis
• Gastric antrum - causes gastric metaplasia
• Any part of the stomach can be involved
• Colonizes overlying mucosa but donot invade mucosa
DR.T.V.RAO MD 19
MAJOR LOCATION OFH.PYLORI
INFECTIONS
DR.T.V.RAO MD 20
 Colonize mucosal lining of stomach & duodenum in
man & animals
• Adherent to gastric surface epithelium or pit epithelial
cells deep within the mucosal crypts adjacent to gastric
mucosal cells
• Mucosa protects the stomach wall from its own gastric
milleu of digestive enzymes and hydrochloric acid
• Mucosa also protects Helicobacter from immune
response
 Most gastric adenocarcinomas and lymphomas are
concurrent with or preceded by an infection with H.
pylori
Pathogenesis of Helicobacter Infections
H.PYLORI INFECTING MUCOSAL
LAYER
DR.T.V.RAO MD 22
PATHOGENESIS OF H.PYLORI.
DR.T.V.RAO MD 23
 Multiple polar, sheathed flagella
• Corkscrew motility enables penetration into viscous
environment (mucus)
 Adhesins: Hemagglutinins; Sialic acid binding
adhesin; Lewis blood group adhesin
 Mucinase: Degrades gastric mucus; Localized
tissue damage
 Urease converts urea (abundant in saliva and
gastric juices) into bicarbonate (to CO2) and
ammonia
• Neutralize the local acid environment
• Localized tissue damage
 Acid-inhibitory protein
Virulence Factors of Helicobacter
H. Pylori Specific T Cell and B Cell Responses
MECHANISM OF H.PYLORI INFECTION
DR.T.V.RAO MD 26
Urease
C=O(NH2)2 + H+ + 2H2O  HCO3
- + 2 (NH4
+)
Urea Bicarbonate Ammonium
ions
And then… HCO3
- 
CO2 + OH-
Urea Hydrolysis
Tissue damage:
 Vacuolating cytotoxin: Epithelial cell damage
 Invasin(s)(??): Poorly defined (e.g., hemolysins;
phospholipases; alcohol dehydrogenase)
Protection from phagocytosis & intracellular killing:
 Superoxide dismutase
 Catalase
Virulence Factors of Helicobacter )
H. Pylori Pathogenesis and Application of
Cutting Edge Technologies
Molecular
biology
Genetics Imaging Cell culture
models
INDICATIONS FOR NONINVASIVE
TESTING FOR H. PYLORI *
• Strongly Recommended
• Dyspepsia
• History of/active peptic ulcer disease
• Gastric MALT lymphoma
• Following gastric cancer resection
• Following peptic ulcer surgery
• First-degree relative with gastric cancer
• Long-term Non-steroidal anti-inflamatory drugs (NSAID)
therapy
* In the absence of alarm signs for gastric cancer or ulcer disease
1. Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167. 2. Talley NJ et al. Aliment Pharmacol Ther.
1999;12:1135.
TYPES OF H. PYLORI TESTS
• Endoscopy
• Rapid urease
tests
• Histology
• Culture
• Serologic (antibody)
• Stool antigen tests
•13C Urea blood
test
• Urea breath tests
•14C-urea
•13C-urea
Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167.
• Detects active infection
• Sensitive and specific
• Non-radioactive
• No special handling
requirements
• Easy to collect and handle
sample
• Not indicated in pediatric
population
13C UREA BREATH TEST
1. Graham DY et al. Am J Gastroenterol. 2001;96:1741. 2. Leodolter A et al. Am J Gastroenterol. 1999;94:2100.
LABORATORY DIAGNOSIS
• Diagnosed by Invasive and Non Invasive tests
• Invasive, Endoscopic Biopsy of Gastric mucosa
• Microscopy – Biopsy
• Culture
• Staining by special stains
• Gram staining
• Culture more sensitive 3 – 7 days
• Biopsy testing for urease detection in urea medium
DR.T.V.RAO MD 33
Laboratory Identification
 Recovered from or detected in endoscopic antral
gastric biopsy material; Multiple biopsies are taken
 Many different transport media
 Culture media containing whole or lysed blood
 Microaerophilic
 Grow well at 37oC, but not at 25 nor 42oC
 Like Campylobacter, does not use carbohydrates,
neither fermentatively nor oxidatively
DIAGNOSIS BY NON INVASIVE
METHODS
• Serology ELISA
• Urea breath test patient
swallows urea solution
In this test patient drinks
urea solutions labeled with
an isotope carbon
If H.pylori is present in the
urea is converted to
ammonia and co2 in the
breath measured.
DR.T.V.RAO MD 35
SUGGESTED GUIDELINES FOR
TREATMENT OF PATIENTS WITH GI OR ULCER
DISEASE
History & Physical Exam
Peptic ulcer
disease
Undifferentiated
dyspepsia
Symptoms
of GERD
Use of NSAIDs
or aspirin
Positive
Eradication
therapy
Confirmation of cure
Test for H. pylori
Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167.
SUGGESTED GUIDELINES FOR
TREATMENT OF PATIENTS WITH GI OR ULCER
DISEASE
History & Physical Exam
Peptic ulcer
disease
Undifferentiated
dyspepsia
Symptoms
of GERD
Use of NSAIDs
or aspirin
Positive
Eradication
therapy
Confirmation of cure
Negative
Treat for PUD,
Initiate PPI therapy,
or discontinue NSAIDs
Test for H. pylori
Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167.
TREATMENT
• Use of antibiotics, bismuth salts
• Ingestion of Bismuth subsalicylate
• Antibiotics Tetracycline's and metronidazole for two
weeks
• Use of Omeprazole
• Clarithromycin
• Do not treat for Asymptomatic colonization
• Drug resistance is a growing problem
DR.T.V.RAO MD 38
• Antibiotic treatment does not always
completely inhibit or kill H. pylori
with potential for antibiotic
resistance. Resistance to antibiotics
is the single most important factor
for declining H. pylori eradication
rates.
• In Japan, resistance to antibiotic
drugs has increased 400% while in
Taiwan, it is 500%. This means that
those who are infected while in
these countries may find the
bacterium rather resistant to their
antibiotic treatments.
EMERGING DRUG RESISTANCE IN H.PYLORI
DR.T.V.RAO MD 39
EPIDEMIOLOGY OF HELICOBACTER INFECTIONS
DR.T.V.RAO MD 40
• Developed Countries:
• United States: 30% of total population infected
• Of those, ~1% per year develop duodenal ulcer
• ~1/3 eventually have peptic ulcer disease(PUD)
• 70% gastric ulcer cases colonized with H. pylori
• Low socioeconomic status predicts H. pylori infection
• Developing Countries:
• Hyperendemic
• About 10% acquisition rate per year for children between 2 and 8 years
of age
• Most adults infected but no disease
• Protective immunity from multiple childhood infections
H.PYLORI CONTINUES TO BE AN
IMPORTANT PATHOGEN
• H. pylori is a transmissible, infectious disease with
potentially serious outcomes
• H. pylori infection may be asymptomatic or cause
dyspepsia
• Eradication therapy can cure H. pylori infection and
prevent morbidity and downstream events such as PUD
and gastric cancer
• Patients with symptoms of upper-GI disease, and who
use aspirin or NSAIDs should be tested for H. pylori
infection
• Programme Created by Dr.T.V.Rao MD
for Medical and Health Care Workers in
the Developing World
• Email
• doctortvrao@gmail.com
DR.T.V.RAO MD 42

helicobacterpylori-120616225853-phpapp01.pdf

  • 1.
  • 2.
    HISTORY OF H.PYLORI • 1890’s: Spirochetes in animal stomachs • 1900’s: Spirochetes in human stomachs • 1954: No bacteria in gastric biopsies of 1000 patients • 1975: Gram negative bacteria in 80% of GU’s (Pseudomonas) • 1983: Warren and Marshall characterize H. pylori • 2005 Nobel prize in 2005
  • 3.
    HELICOBACTER PYLORI Background Human stomachlong considered inhospitable for bacteria Spiral shaped organisms occasionally visualized in gastric mucous layer, but no evidence of disease association Organism classified first as Campylobacter pylori Now Helicobacter pylori Other species of Helicobacter isolated from stomach, intestine of other animals Marshall and Warren culture organism from human gastric mucosa and show association with gastric inflammation DR.T.V.RAO MD 3
  • 4.
    HELICOBACTER ( WARREN ANDMARSHAL ) • Campylobacter like organisms • Spiral shaped colonizes Gastric mucosa • Etiological agent in Gastritis and peptic ulcer • Most important bacteria. Helicobacter pylori Colonizes 50 % of the Individuals DR.T.V.RAO MD 4
  • 5.
    WARREN AND MARSHALWINS NOBEL PRIZE DR.T.V.RAO MD 5
  • 6.
    GENERAL CHARACTERISTICS OF HELICOBACTER DR.T.V.RAOMD 6 • Helicobacter pylori is major human pathogen associated with gastric antral epithelium in patients with active chronic gastritis • Stomach of many animal species also colonized • Urease (gastric strains only), mucinase, and catalase positive highly motile microorganisms • Other Helicobacters: H. cinnaedi and H. fenneliae • Colonize human intestinal tract • Isolated from homosexual men with proctitis, proctocolitis, enteritis, and bacteremia and are often transmitted through sexual practices
  • 7.
    A silver stainof H. pylori on gastric mucus- secreting epithelial cells (x1000). From Dr. Marshall's stomach biopsy taken 8 days after he drank a culture of H. pylori (1985). DR.T.V.RAO MD 7
  • 8.
    HELICOBACTER PYLORI • Gram–ve spiral shaped , motile with unipolar tuft of lopotrichus flagella DR.T.V.RAO MD 8
  • 9.
    H. PYLORI BACTERIA •Gram negative • Spiral rod • Unipolar flagella • Microaerophilic • Urease positive* *Most important character *Scanning microscopic view of H. pylori
  • 10.
    MORPHOLOGY & PHYSIOLOGYOF HELICOBACTER DR.T.V.RAO MD 10 • Gram-negative; Helical (spiral or curved) (0.5-1.0 um X 2.5-5.0 um); Blunted/rounded ends in gastric biopsy specimens; Cells become rod-like and coccoid on prolonged culture • Produce urease, mucinase, and catalase • H. pylori tuft (lophotrichous) of 4-6 sheathed flagella (30um X 2.5nm) attached at one pole • Single polar flagellum on H. fennellae & H. cinaedi • Smooth cell wall with unusual fatty acids
  • 11.
    • Transmissible • Oral-oraland oral- fecal • Infects the human stomach • Produces inflammatory response • This brings up the point of the importance of “hand washing” H. PYLORI INFECTION TRANSMISSION
  • 12.
    DYNAMICS OF H.PYLORIINFECTION DR.T.V.RAO MD 12
  • 13.
    CULTURING AND BIOCHEMICAL CHARACTERS •Grows on chocolate agar, Campylobacter media • Grows under Microaerophilic conditions • With presence of 5 – 20% co2 • Oxidase + • Catalase – • Urease strongly +++ • H2S DR.T.V.RAO MD 13
  • 14.
    H. PYLORI PATHOGENESIS BACTERIALVIRULENCE FACTORS (CAG- PAI)( 37000 B-P – 29 GENES) • Type IV secretions apparatus(1) (translocate cag A) • Possible insertion by needle like organelle coated with a sheath (Cag 7 protein) [Rohde et al] • Phosphorylated + binds to SHP-2 tyrosine Phosphates Cytokine Production Growth Factor IL- 8+ chemokines Like cellular response (1) Odenbreit S, et al. Science 2000;287:1497-1500
  • 15.
    H. PYLORI PATHOGENESIS BACTERIALVIRULENCE FACTORS Ingestion Evasion + Entrance of Mucus 1 Layer (Motility + Urea I) 2 Binding 3 Insertion 4 Intra cellular pathway
  • 16.
    HELICOBACTER PYLORI ANDPEPTIC ULCER DISEASE HISTOPATHOLOGY WITH SPECIAL STAINS .
  • 17.
  • 18.
    H. PYLORI PATHOGENESIS THEROLE OF CYTOKINES I. Alter secretion of mucus II. TNF–α IL–Iß, INF- 1Y • ↑ Gastrin release Stimulate parietal cells ↑ Acid secretion I. TNF–α ↓ D cells number ↓ Somatostatin ↑ Acid secretion
  • 19.
    PATHOLOGY AND PATHOGENESIS •H.pylori colonizes gastric mucosa • Spread by oral – oral contact • Feco oral spread prominent • Poverty and overcrowding predisposes • Poor Hygiene • Causes mild to acute gastritis • Gastric antrum - causes gastric metaplasia • Any part of the stomach can be involved • Colonizes overlying mucosa but donot invade mucosa DR.T.V.RAO MD 19
  • 20.
  • 21.
     Colonize mucosallining of stomach & duodenum in man & animals • Adherent to gastric surface epithelium or pit epithelial cells deep within the mucosal crypts adjacent to gastric mucosal cells • Mucosa protects the stomach wall from its own gastric milleu of digestive enzymes and hydrochloric acid • Mucosa also protects Helicobacter from immune response  Most gastric adenocarcinomas and lymphomas are concurrent with or preceded by an infection with H. pylori Pathogenesis of Helicobacter Infections
  • 22.
  • 23.
  • 24.
     Multiple polar,sheathed flagella • Corkscrew motility enables penetration into viscous environment (mucus)  Adhesins: Hemagglutinins; Sialic acid binding adhesin; Lewis blood group adhesin  Mucinase: Degrades gastric mucus; Localized tissue damage  Urease converts urea (abundant in saliva and gastric juices) into bicarbonate (to CO2) and ammonia • Neutralize the local acid environment • Localized tissue damage  Acid-inhibitory protein Virulence Factors of Helicobacter
  • 25.
    H. Pylori SpecificT Cell and B Cell Responses
  • 26.
    MECHANISM OF H.PYLORIINFECTION DR.T.V.RAO MD 26
  • 27.
    Urease C=O(NH2)2 + H++ 2H2O  HCO3 - + 2 (NH4 +) Urea Bicarbonate Ammonium ions And then… HCO3 -  CO2 + OH- Urea Hydrolysis
  • 28.
    Tissue damage:  Vacuolatingcytotoxin: Epithelial cell damage  Invasin(s)(??): Poorly defined (e.g., hemolysins; phospholipases; alcohol dehydrogenase) Protection from phagocytosis & intracellular killing:  Superoxide dismutase  Catalase Virulence Factors of Helicobacter )
  • 29.
    H. Pylori Pathogenesisand Application of Cutting Edge Technologies Molecular biology Genetics Imaging Cell culture models
  • 30.
    INDICATIONS FOR NONINVASIVE TESTINGFOR H. PYLORI * • Strongly Recommended • Dyspepsia • History of/active peptic ulcer disease • Gastric MALT lymphoma • Following gastric cancer resection • Following peptic ulcer surgery • First-degree relative with gastric cancer • Long-term Non-steroidal anti-inflamatory drugs (NSAID) therapy * In the absence of alarm signs for gastric cancer or ulcer disease 1. Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167. 2. Talley NJ et al. Aliment Pharmacol Ther. 1999;12:1135.
  • 31.
    TYPES OF H.PYLORI TESTS • Endoscopy • Rapid urease tests • Histology • Culture • Serologic (antibody) • Stool antigen tests •13C Urea blood test • Urea breath tests •14C-urea •13C-urea Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167.
  • 32.
    • Detects activeinfection • Sensitive and specific • Non-radioactive • No special handling requirements • Easy to collect and handle sample • Not indicated in pediatric population 13C UREA BREATH TEST 1. Graham DY et al. Am J Gastroenterol. 2001;96:1741. 2. Leodolter A et al. Am J Gastroenterol. 1999;94:2100.
  • 33.
    LABORATORY DIAGNOSIS • Diagnosedby Invasive and Non Invasive tests • Invasive, Endoscopic Biopsy of Gastric mucosa • Microscopy – Biopsy • Culture • Staining by special stains • Gram staining • Culture more sensitive 3 – 7 days • Biopsy testing for urease detection in urea medium DR.T.V.RAO MD 33
  • 34.
    Laboratory Identification  Recoveredfrom or detected in endoscopic antral gastric biopsy material; Multiple biopsies are taken  Many different transport media  Culture media containing whole or lysed blood  Microaerophilic  Grow well at 37oC, but not at 25 nor 42oC  Like Campylobacter, does not use carbohydrates, neither fermentatively nor oxidatively
  • 35.
    DIAGNOSIS BY NONINVASIVE METHODS • Serology ELISA • Urea breath test patient swallows urea solution In this test patient drinks urea solutions labeled with an isotope carbon If H.pylori is present in the urea is converted to ammonia and co2 in the breath measured. DR.T.V.RAO MD 35
  • 36.
    SUGGESTED GUIDELINES FOR TREATMENTOF PATIENTS WITH GI OR ULCER DISEASE History & Physical Exam Peptic ulcer disease Undifferentiated dyspepsia Symptoms of GERD Use of NSAIDs or aspirin Positive Eradication therapy Confirmation of cure Test for H. pylori Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167.
  • 37.
    SUGGESTED GUIDELINES FOR TREATMENTOF PATIENTS WITH GI OR ULCER DISEASE History & Physical Exam Peptic ulcer disease Undifferentiated dyspepsia Symptoms of GERD Use of NSAIDs or aspirin Positive Eradication therapy Confirmation of cure Negative Treat for PUD, Initiate PPI therapy, or discontinue NSAIDs Test for H. pylori Malfertheiner P, et al. Aliment Pharmacol Ther. 2002;16:167.
  • 38.
    TREATMENT • Use ofantibiotics, bismuth salts • Ingestion of Bismuth subsalicylate • Antibiotics Tetracycline's and metronidazole for two weeks • Use of Omeprazole • Clarithromycin • Do not treat for Asymptomatic colonization • Drug resistance is a growing problem DR.T.V.RAO MD 38
  • 39.
    • Antibiotic treatmentdoes not always completely inhibit or kill H. pylori with potential for antibiotic resistance. Resistance to antibiotics is the single most important factor for declining H. pylori eradication rates. • In Japan, resistance to antibiotic drugs has increased 400% while in Taiwan, it is 500%. This means that those who are infected while in these countries may find the bacterium rather resistant to their antibiotic treatments. EMERGING DRUG RESISTANCE IN H.PYLORI DR.T.V.RAO MD 39
  • 40.
    EPIDEMIOLOGY OF HELICOBACTERINFECTIONS DR.T.V.RAO MD 40 • Developed Countries: • United States: 30% of total population infected • Of those, ~1% per year develop duodenal ulcer • ~1/3 eventually have peptic ulcer disease(PUD) • 70% gastric ulcer cases colonized with H. pylori • Low socioeconomic status predicts H. pylori infection • Developing Countries: • Hyperendemic • About 10% acquisition rate per year for children between 2 and 8 years of age • Most adults infected but no disease • Protective immunity from multiple childhood infections
  • 41.
    H.PYLORI CONTINUES TOBE AN IMPORTANT PATHOGEN • H. pylori is a transmissible, infectious disease with potentially serious outcomes • H. pylori infection may be asymptomatic or cause dyspepsia • Eradication therapy can cure H. pylori infection and prevent morbidity and downstream events such as PUD and gastric cancer • Patients with symptoms of upper-GI disease, and who use aspirin or NSAIDs should be tested for H. pylori infection
  • 42.
    • Programme Createdby Dr.T.V.Rao MD for Medical and Health Care Workers in the Developing World • Email • [email protected] DR.T.V.RAO MD 42